CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers

RSPR Pharma AB

Overview

This is an investigation of the efficacy and safety of CRD007 in Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD) and symptomatic carriers.

Study Type

INTERVENTIONAL

Conditions

Duchenne Muscular Dystrophy Becker Muscular Dystrophy

Interventions

CRD007DRUG

Eligibility

Sex: ALLMin age: 2 YearsMax age: 11 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Documented diagnosis of dystrophinopathy Exclusion Criteria: * Severe functional impairment

Locations (1)

Unnamed facility

Stockholm, Sweden

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.